Faecal microbiota transplantation shows no benefit in IBS trial

A phase 3 randomised, double-blind, placebo-controlled trial (REFIT2) conducted at five Norwegian hospitals tested a single rectal enema of faecal microbiota transplantation from healthy donors versus participants' own stool in 448 adults with moderate-to-severe IBS. At 90 days, 40% of the donor transplant group and 38% of the placebo group achieved a reduction of 75 points or more in IBS-SSS score, a difference the trial reported as not statistically significant, with similar rates of adverse events between groups. The trial's investigators concluded that faecal microbiota transplantation did not show clinical benefit and suggested microbiota modulation alone might be insufficient for symptom improvement in IBS.

Most relevant for: Adults aged 18-65 with moderate-to-severe irritable bowel syndrome diagnosed by Rome IV criteria.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.